Takara Bio Inc. (4974.T) JPX

Currency In JPY

Key Executives

Name	Title	Year Born
Tsuyoshi Miyamura	Chief Executive Officer, President & Representative Director	1963
Andrew Farmer	Head of Research and Development	N/A
Ikuei Nukaya	Managing Executive Officer & Head of Quality Control Headquarters	N/A
Katsuhiko Kusakabe	Vice President, Executive Officer & Director	1961
Akira Kodera	Managing Executive Officer & Head of Sales Division	N/A
Hiroki Tomohisa	Executive Officer	N/A
Kyoko Nakajima	Senior Executive Officer & Head of SCM Division	N/A
Noritaka Nishiwaki	Executive Officer, Deputy GM of Corporate Headquarters & GM of Human Resources Department	N/A
Junichi Mineno	Vice President, Executive Officer & Director	1960
Yoh Hamaoka	Vice President, Executive Officer & Director	1962

Name

Title

Pay

Year Born

Tsuyoshi Miyamura

Chief Executive Officer, President & Representative Director

1963

Andrew Farmer

Head of Research and Development

N/A

Ikuei Nukaya

Managing Executive Officer & Head of Quality Control Headquarters

N/A

Katsuhiko Kusakabe

Vice President, Executive Officer & Director

1961

Akira Kodera

Managing Executive Officer & Head of Sales Division

N/A

Hiroki Tomohisa

Executive Officer

N/A

Kyoko Nakajima

Senior Executive Officer & Head of SCM Division

N/A

Noritaka Nishiwaki

Executive Officer, Deputy GM of Corporate Headquarters & GM of Human Resources Department

N/A

Junichi Mineno

Vice President, Executive Officer & Director

1960

Yoh Hamaoka

Vice President, Executive Officer & Director

1962

Description

Takara Bio Inc. is a global biotechnology enterprise, operating through its subsidiaries across Japan, the United States, China, other parts of Asia, Europe, and other international markets. Its operations are divided into two core segments: Bioindustry and Gene Therapy. Within its Bioindustry segment, the company develops research reagents and scientific instrumentation. It also delivers Contract Development and Manufacturing Organization (CDMO) services, supporting both academic and corporate clients in life sciences research and development. These CDMO offerings encompass contract services for developing regenerative medicine products, alongside ancillary services like quality control, safety evaluations, and cell banking. Furthermore, Takara Bio assists with genetic analysis and testing, including human genome sequencing, cancer gene analysis, and intestinal flora studies. It also provides advanced support for genetic engineering research, leveraging cutting-edge technologies and equipment for tasks like genome editing. The Gene Therapy segment focuses on the development and commercialization of a diverse portfolio of gene therapies. This includes Canerpaturev, an oncolytic virus derived from an attenuated herpes simplex virus type 1, designed to induce antitumor activity and tumor lysis through local injection. The segment is also advancing siTCR gene therapy, currently in Phase I/II clinical trials for synovial sarcoma, and CD19 chimeric antigen receptor therapy, also in Phase I/II trials for adult acute lymphoblastic leukemia. Additionally, the company supplies RetroNectin, a key component for gene therapy applications. Established in 2002, Takara Bio Inc. maintains its headquarters in Kusatsu, Japan, and operates as a subsidiary of Takara Holdings Inc.